Abstract
Objective: The affinity of (+)-, (−)- and (±)-fluvastatin, a new synthetic HMG-CoA reductase inhibitor developed as a racemate, for specific human P450 monooxygenases in liver microsomes was compared with that of the pharmacologically active acidic forms of lovastatin, pravastatin and simvastatin.
Methods:
Affinity was determined as the inhibitory potency for prototype reactions for 3 major drug metabolising enzymes: diclofenac 4′-hydroxylation (CYP2C9), dextromethorphan O-demethylation (CYP2D6), and midazolam 1′-hydroxylation (CYP3A4).
Results:
Lovastatin acid, pravastatin and simvastatin acid displayed moderate affinity for all three P450 isozymes (estimated Ki > 50 μmol⋅l−1). Racemic and (+)- and (−)-fluvastatin showed moderate affinity (estimated Ki > 50 μmol⋅l−1) for CYP2D6 and CYP3A4, whereas their affinity for CYP2C9 was high (estimated Ki < 1 μmol⋅l−1). Diclofenac 4′-hydroxylation was competitively and stereoselectively inhibited, with measured Ki’s of 0.06 and 0.28 μmol⋅l−1 for (+)- and (−)-fluvastatin, respectively.
Conclusion:
Fluvastatin selectively inhibits a major drug metabolising enzyme (CYP2C9), the (+)-isomer (pharmacologically more active) showing 4–5 fold higher affinity. As already reported for lovastatin and simvastatin, in vivo drug interactions by inhibition of liver oxidation of CYP2C9 substrates (e.g. hypoglyceamic sulphonylureas and oral anticoagulants) may be expected.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 9 June 1995/Accepted in revised form: 7 November 1995
Rights and permissions
About this article
Cite this article
Transon, C., Leemann, T. & Dayer, P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. E J Clin Pharmacol 50, 209–215 (1996). https://doi.org/10.1007/s002280050094
Issue Date:
DOI: https://doi.org/10.1007/s002280050094